The Food and Drug Administration, the US regulator, is to unveil a pioneering mechanism this year that rewards pharmaceutical companies for their research into previously neglected diseases with vouchers for accelerated drug reviews.
These vouchers – highly valuable as they might speed up market access for new medicines – can then be sold on to other companies, which can use them for any drug.
